Quality control of cervical cytology using a 3-type HPV mRNA test increases screening program sensitivity of cervical intraepithelial neoplasia grade 2+ in young Norwegian women—A cohort study

Within 2021, Norway intends to complete implementation of HPV DNA-based primary screening for cervical cancer for women 34–69 years, while continue cytology-based screening for women 25–33 years. Over the recent years, the incidence of cervical cancer has increased by 30% among women younger than 40...

Descripción completa

Detalles Bibliográficos
Autores principales: Westre, Bjørn, Giske, Anita, Guttormsen, Hilde, Wergeland Sørbye, Sveinung, Skjeldestad, Finn Egil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830931/
https://www.ncbi.nlm.nih.gov/pubmed/31689301
http://dx.doi.org/10.1371/journal.pone.0221546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830931/
https://www.ncbi.nlm.nih.gov/pubmed/31689301
http://dx.doi.org/10.1371/journal.pone.0221546

Ejemplares similares